Organization
Radiant Research
1 abstract
Abstract
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL-DOSE STUDY OF THE SAFETY OF APRATASTAT (TMI-005), A NOVEL ORAL DUAL INHIBITOR OF TNF-ALPHA-CONVERTING ENZYME/METALLOPROTEINASE, IN PATIENTS WITH RHEUMATOID ARTHRITIS ON A BACKGROUND OF METHOTREXAOrg: Research Center for Health Policy and Economics, Radiant Research, Dallas, Altoona Center for Clinical Research, Duncansville, Duncansville,